Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Swarm-T
- Development stage
- Preclinical
- Lead developer
- Swarm Oncology
- Modality
- Patient-derived iPSCs → iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies, Hematopoietic Stem Cells → Adult Stem Cells → Stem Cell Therapies → Cell Therapies, CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Mesenchymal Stem Cells → Adult Stem Cells → Stem Cell Therapies → Cell Therapies, TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Tumor-Infiltrating Lymphocytes (TILs) → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
Swarm-T is a novel, highly differentiated personalized T cell therapy platform developed by Swarm Oncology for the treatment of advanced solid cancers. The platform integrates in vivo immune priming with proprietary ex vivo cell processing to generate large numbers of potent, non-exhausted T cells with specific phenotypes optimized to home to, infiltrate, and kill cancer cells. This approach aims to overcome major limitations of current immunotherapy by enabling durable immune responses and long-term remission in patients with metastatic or advanced solid tumors. The technology is designed for autologous use (using the patient’s own cells) and leverages both innovative manufacturing processes and immune system modulation[2][3].
- Brand names
- Swarm-T
- Other names
- Swarm-T
02
Targets
pMHC-I (Peptide–MHC class I complex)
Beyond the preview
Go deeper on Swarm-T.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Swarm-T.